Institute for Wealth Management’s ANI Pharmaceuticals ANIP Stock Holding History

Institute for Wealth Management’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.8K	Buy	+275	New	+$22.1K	﹤0.01%	1088

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

MMA

Mizuho Markets Americas New York $6.37B AUM 47.14% 1-Year Est. Return

PCM

Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Institute for Wealth Management's ANIP Position: Q2 2026 in Review

Institute for Wealth Management opened a new position in ANI Pharmaceuticals (ANIP) in Q2 2026: 275 shares worth $22.8K. The stake represents ﹤0.01% of the portfolio and ranks #1088 among its holdings.

116 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

Institute for Wealth Management held 275 shares of ANI Pharmaceuticals worth $22.8K as of Q2 2026.
ANI Pharmaceuticals was a new Institute for Wealth Management position in Q2 2026.
ANI Pharmaceuticals made up ﹤0.01% of Institute for Wealth Management's portfolio in Q2 2026, its #1088 holding.
116 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Institute for Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.